Senseonics Holdings, Inc. (NASDAQ: SENS)

Senseonics Holdings, Inc. is a medical technology company focused on the development and commercialization of a long term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes. Its flagship product, the Eversense system, includes the Eversense E3 and Eversense 365 CGM systems, which measure glucose levels via an under the skin sensor, a removable smart transmitter, and a mobile app for up to twelve months or six months of continuous wear.

The company generates revenue primarily from the sale of the Eversense CGM system, which comprises the sensor pack containing the sensor, insertion tool, and adhesive patches; the smart transmitter pack containing the transmitter and charger; and, where applicable, procedure revenue associated with sensor insertion and removal. Revenue is also derived through distribution agreements with partners such as Ascensia Diabetes Care Holdings AG, which previously held exclusive rights to market Eversense worldwide before the transfer of commercial operations back to Senseonics in 2026.

• no_segments_reported.

Senseonics operates in the competitive continuous glucose monitoring market alongside larger players such as Dexcom, Medtronic, and Abbott. Its competitive advantages stem from the Eversense system’s unusually long sensor duration of up to one year, its implantable design that separates the sensor from the external transmitter, and features such as on body vibration alerts and real time smartphone connectivity. While competitors Dexcom and Abbott offer factory calibrated systems with shorter wear periods, Senseonics differentiates itself through longer wear time and the ability to share glucose data with friends, family, and clinicians via its app.

The company’s customers include people with diabetes who use the Eversense system for glucose monitoring, as well as healthcare providers who prescribe and insert the device. Senseonics also works with third party payors to secure coverage; in the United States it reports approximately 300,000,000 covered lives through agreements with insurers such as UnitedHealthcare and Medicare.